Abstract:Background: ApoA5, the newest member of the apolipoprotein family, is expressed exclusively in the liver.Although plasma ApoA5 concentrations in humans are very low (114-258 ng/mL) and ~1,000-fold lower than those of ApoB100 on a molar basis, human and mouse studies have clearly shown a key role of ApoA5 in plasma triglyceride (TG) homeostasis.Because ~20% of ApoA5 is secreted into the circulation and its concentration is 7-fold higher in the liver than in plasma, we hypothesize that ApoA5 plays a critical role in regulating hepatic TG metabolism and ApoA5 deficiency profoundly perturbs the balance of daily input and output of fatty acids (FA) in the liver.Methods: Male ApoA5 KO and WT mice were fed a chow diet for 12 mo.Liver pathology was examined by H&E and Sirius Red staining.Lipid droplets (LD) and endoplasmic reticulum (ER) and Golgi fractions were isolated from homogenized liver by ultracentrifugation.Gene expression and protein content were studied by qRT-PCR and Western blots.Lipidomic analysis of liver was performed by ESI-MS/MS.Results: During the 12-mo period, on chow, ApoA5 deficiency significantly reduced TG disposal by inhibiting FA β-oxidation through repressing carnitine palmitoyltransferase-1, coupled with reduced energy expenditure.In WT mice, because it is a LD-associated protein, ApoA5 guided TG-rich LD to the ER for VLDL assembly and subsequently to the Golgi apparatus for hepatic VLDL secretion through its interaction with Plin2, Cideb and ApoB100.ApoA5 deficiency reduces hepatic VLDL secretion by impairing its lipidation and maturation.As a result, accumulation of excess TG within the cytoplasm of hepatocytes induced the formation of numerous large LD, leading to liver steatosis.ApoA5 deficiency significantly increased de novo synthesis of ceramides, the major FA metabolites, by enhancing hepatic serine palmitoyltransferase activity.Due to their hepatocellular lipotoxicity, increased ceramides induced hepatic lipoapoptosis through TNFα by stimulating both caspase-induced apoptosis and ROS-mediated mitochondrial dysfunction in ApoA5 KO, but not WT mice.These alterations triggered NASH with a main histological feature of hepatocellular ballooning in ApoA5 KO mice.Ceramide-induced hepatocyte apoptosis and activation of hepatic stellate cells promoted fibrogenesis by triggering a profibrogenic gene program, leading to liver fibrosis.Conclusions: ApoA5 deficiency in chow-fed mice over a long period leads to spontaneous development of NAFLD, gradually evolving from simple steatosis to NASH, and subsequently to liver fibrosis, which closely recapitulates many aspects of the pathogenic process of NAFLD in patients.These innovative studies will help us understand the mechanisms underlying the critical role of ApoA5 in the pathogenesis of NAFLD and provide novel targets to combat NAFLD by pharmacological intervention.

Is Apolipoprotein A-IV Rate Limiting in the Intestinal Transport and Absorption of Triglyceride?

The Role of Apolipoprotein A-IV in Regulating Glucagon-Like Peptide-1 Secretion.

ApoB48 as an Efficient Regulator of Intestinal Lipid Transport

APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries

Apolipoprotein A-IV involves in glucose and lipid metabolism of rat

The intestine as a source of apolipoprotein A1.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

Effects and mechanisms of apolipoprotein A-V on the regulation of lipid accumulation in cardiomyocytes

ABCG5/G8 deficiency results in reduced intestinal cholesterol and fatty acid transport

Apolipoprotein A5 regulates intracellular triglyceride metabolism in adipocytes

41 Cholesterol 7Α-Hydroxylase (CYP7A1) Mediates Resistance to High-Fat Diet-Induced Obesity and Diabetes Through Elevated Tauro-β-Muricholic Acid and Inhibition of Farnesoid X Receptor Signaling in the Intestine

DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis

Hepatic ABCA1 deficiency is associated with delayed apolipoprotein B secretory trafficking and augmented VLDL triglyceride secretion

Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits

Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis

Aggravated Restenosis and Atherogenesis in ApoCIII Transgenic Mice but Lack of Protection in ApoCIII Knockouts: the Effect of Authentic Triglyceride-Rich Lipoproteins with and Without ApoCIII.

Augmented Atherogenesis in LDL Receptor Deficient Mice Lacking Both Macrophage ABCA1 and ApoE.

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux

Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis.

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?